{"product_id":"bms-ansoff-matrix","title":"Bristol Myers Squibb Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bristol Myers Squibb Amsoff Matrix Analysis gives a clear view of the company’s growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the analysis, so you can review the actual style and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEliquis access defense before 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb is defending Eliquis with payer access, adherence support, and tight co-promotion discipline ahead of the U.S. generic window around 2028. Eliquis is still a core cash engine, with latest reported annual sales above $13 billion, so share defense matters more than category expansion. This is market penetration in a mature, one-drug anticoagulant market, not a reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpdivo and Yervoy label breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpdivo and Yervoy stay broad across more than 10 solid-tumor settings, including lung, kidney and melanoma, so Bristol Myers Squibb keeps them built into routine oncology care. In 2025, that label breadth still matters because prescriber familiarity and regimen switching costs are mostly clinical and behavioral, not price-driven. It is a clear share-defense play: more line extensions and combo use keep the brands anchored in practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreyanzi center utilization gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Breyanzi stays a six-figure CAR-T therapy, so every added certified site can shift meaningful revenue. Bristol Myers Squibb is expanding treatment-center capacity and simplifying logistics to cut referral friction, which still bottlenecks cell-therapy volume. That makes center utilization a direct market-penetration lever, with even small share gains able to move a high-value franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCamzyos cardiology conversion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Bristol Myers Squibb kept scaling Camzyos in obstructive hypertrophic cardiomyopathy by moving patients from referral to treatment through cardiology networks. The lift comes from solving diagnosis and specialist-awareness gaps, with REMS training and key opinion leader outreach aimed at converting the same eligible pool rather than expanding the indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSotyktu and Reblozyl payer depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is deepening payer coverage and prescriber reach for Sotyktu and Reblozyl, which supports more scripts as each brand moves through 2025. Both are still earlier than Eliquis, so there is more room to expand access and convert trial use into repeat prescribing in 2026. This market penetration step matters because newer specialty brands must replace legacy revenue before mature portfolios fade.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol Myers Squibb Defends Eliquis, Grows Breyanzi Through Wider Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Bristol Myers Squibb is using market penetration to defend Eliquis, Opdivo, Yervoy, Breyanzi, Camzyos, Sotyktu, and Reblozyl in their current pools, not to chase new categories. Eliquis still topped $13 billion in annual sales, so payer access and adherence support stay central. Breyanzi and Camzyos grow by widening site and specialist reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025 focus\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003eShare defense\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$13B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreyanzi\u003c\/td\u003e\n\u003ctd\u003eMore centers\u003c\/td\u003e\n\u003ctd\u003eSix-figure therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Bristol Myers Squibb’s growth strategy through the four core directions of the Amsoff Matrix\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Bristol Myers Squibb Ansoff Matrix to quickly relieve growth-planning confusion and align strategy across products and markets.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCamzyos rollout beyond the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCamzyos is moving country by country outside the U.S., with Europe and Japan key because specialist cardiology centers can manage its monitoring and reimbursement. In 2025, Bristol Myers Squibb kept expanding ex-U.S. access after earlier approvals in the EU and Japan, so the same drug now reaches a larger addressable market. That matters because obstructive hypertrophic cardiomyopathy affects about 1 in 500 people.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEliquis growth in 3 major regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Bristol Myers Squibb kept pushing Eliquis in Europe, Japan, and China by widening reimbursement and converting approvals into new patient starts. Eliquis is now a mature anticoagulant, so growth comes from physician adoption, not brand education; BMS still relies on a market with over 100-country reach. In Japan and Europe, broader payer access and guideline use remain the main volume drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReblozyl access in more hematology systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb is expanding Reblozyl access across more ex-U.S. hematology and oncology systems as formulary wins stack up in 2025, and the drug is already approved in more than 60 markets. Large tertiary-care hospitals matter most here because anemia care is usually centralized, so one access win can open many patients at once.\u003c\/p\u003e\n\u003cp\u003eThis is classic market development: the same product goes into new countries and hospital networks without changing its profile. That matters for scale, because Reblozyl added global reach while Bristol Myers Squibb still kept the launch playbook focused on specialist centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreyanzi and Abecma center expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is still widening Breyanzi and Abecma access by adding certified CAR-T centers, so this is market development driven by site readiness, not by weak demand. Every new center expands patient reach and helps convert approved therapy into real sales, especially as collection, manufacturing, and infusion workflows get smoother. Europe and selected Asia-Pacific markets are the key lanes because reimbursement, hospital capability, and center certification are advancing there first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology reimbursement in China and Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is using market development in China and Japan by filing existing oncology drugs, then pushing through pricing and reimbursement deals to turn approved products into new regional sales. China had about 4.8 million new cancer cases in 2022, while Japan had about 1.0 million, so patient demand is large even when access moves slowly.\u003c\/p\u003e\n\u003cp\u003eThat makes execution more important than branding: local launch timing, payer proof, and hospital uptake decide revenue. In an Ansoff view, this is low-product, new-market growth with real upside if reimbursement lands fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol Myers Squibb’s 2025 Growth Push: New Markets, Not New Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb is using market development by taking existing drugs into new countries and care sites in 2025, especially Camzyos, Reblozyl, and Breyanzi. The move is strongest where specialist centers and reimbursement unlock use: Camzyos for hypertrophic cardiomyopathy, Reblozyl in 60+ markets, and Breyanzi through certified CAR-T sites. This is low-product, new-market growth with access, not R\u0026amp;D, as the main lever.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBristol Myers Squibb Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Bristol Myers Squibb Amsoff Matrix Analysis document you’ll receive upon purchase—no surprises, just the full professional version. The preview below is taken directly from the complete report, and after checkout you’ll unlock the entire detailed file. What you see here is exactly what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpdivo Qvantig shifts administration time\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb is using Opdivo Qvantig to shift Opdivo from IV infusion to a 3-to-5-minute subcutaneous dose, versus roughly 30 to 60 minutes by infusion. That can raise chair turnover and make treatment easier for patients, so it is a clear product development move in Ansoff terms. It is also a direct lifecycle extension for a flagship immuno-oncology brand that still anchors the company’s 2025 oncology portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCobenfy adds a new schizophrenia mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb’s Cobenfy, approved in September 2024, is a first-in-class schizophrenia drug that uses muscarinic receptor activity, not dopamine blockade. That makes it a true product-development move in the Ansoff Matrix, not a copycat antipsychotic.\u003c\/p\u003e\n\u003cp\u003eThe U.S. launch opened a fresh prescription base in a chronic CNS market where long-term treatment drives repeat use. Bristol Myers Squibb said Cobenfy reached U.S. patients within months of launch, showing internal R\u0026amp;D turning into sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKrazati combinations widen oncology reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Bristol Myers Squibb is advancing Krazati (adagrasib) into KRAS G12C colorectal cancer combinations, including cetuximab-based regimens, moving it beyond its lung-cancer base. KRAS G12C shows up in about 3% to 4% of colorectal cancers and about 13% of non-small cell lung cancer, so the addressable pool expands meaningfully.\u003c\/p\u003e\n\u003cp\u003eThat makes this a clear product-development play in the Ansoff Matrix: same drug, new use, bigger reach. Combination therapy can also extend the life of a targeted asset by improving response depth and delaying resistance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreyanzi moves earlier in lymphoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is moving Breyanzi into earlier-line lymphoma, which widens the eligible patient pool and can speed uptake as treatment centers gain experience.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Breyanzi remains a key growth driver, with 2024 sales of $1.2 billion and continued label expansion in large B-cell lymphoma settings that support a bigger addressable market.\u003c\/p\u003e\n\u003cp\u003eThis strategy can raise revenue without a new molecule, using the same CAR-T platform across more lines of therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCamzyos lifecycle studies continue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is keeping Camzyos in active lifecycle studies for new cardiomyopathy and heart-failure uses in 2025, so this is a product development play in the Ansoff Matrix. The logic is simple: one approved brand, one sales channel, more patient groups.\u003c\/p\u003e\n\u003cp\u003eThat matters because label expansion can widen Camzyos demand without rebuilding the commercial stack from scratch. In 2025 and 2026, breadth of lifecycle data can matter as much as first-launch momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol Myers Squibb Bets on Faster Dosing and New Uses for 2025 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb’s Product Development centers on label expansion and new delivery formats for 2025 growth. Opdivo Qvantig shifts dosing to 3–5 minutes, while Cobenfy, Krazati, Breyanzi, and Camzyos widen use into new patients and settings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 move\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo Qvantig\u003c\/td\u003e\n\u003ctd\u003e3–5 min SC dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKrazati\u003c\/td\u003e\n\u003ctd\u003eKRAS G12C CRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKaruna deal creates a neuroscience platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb's $14.0 billion Karuna Therapeutics deal pushed it into neuroscience, adding Cobenfy and moving beyond oncology. In 2025, that gave Bristol Myers Squibb a first-in-class schizophrenia launch in a market with about 24 million people affected worldwide. This is a clear new-market, new-product diversification move under Ansoff Matrix logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRayzeBio adds radiopharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb's about $4.1 billion RayzeBio buy added radiopharmaceuticals, giving the company a third oncology leg beside antibodies, pills, and cell therapy. That move widens its science platform and shifts the Ansoff Matrix toward diversification, since it enters an isotope-based treatment field with a different clinical and manufacturing model. With top 2025 focus on expanding oncology depth, this deal also opens a longer growth runway beyond legacy assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMirati broadens precision-oncology exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb’s $5.8 billion Mirati deal added Krazati, giving it direct exposure to KRAS G12C precision oncology, a separate genetic segment inside oncology. In 2025, that matters because KRAS G12C remains a high-value target in solid tumors, and Krazati keeps Bristol Myers Squibb in a niche with limited direct peers. This is diversification inside oncology, but it is also a shift into a distinct molecular driver with its own clinical and commercial path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy builds a second operating model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCell therapy gives Bristol Myers Squibb a second operating model: Breyanzi and Abecma need cell collection, specialized manufacturing, cold-chain logistics, and treatment-center coordination, not just pill or antibody sales.\u003c\/p\u003e\n\u003cp\u003eThat makes the business harder to copy and less tied to one launch path.\u003c\/p\u003e\n\u003cp\u003eWith 2 approved CAR-T products in 2025, Bristol Myers Squibb reduces dependence on any single modality and deepens its oncology mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroscience can become a second pillar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb is trying to make neuroscience a durable second pillar beside oncology and hematology. Cobenfy, launched in 2024 after the $14 billion Karuna deal, gives Bristol Myers Squibb a real CNS base; if it adds 1 or 2 more indications in the next 2 to 3 years, the mix gets less tied to a few big cancer drugs. That is the diversification payoff management wants after the 2024 acquisition wave.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol Myers Squibb Broadens Beyond Blockbusters in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb’s diversification push in 2025 is real: Karuna, RayzeBio, and Mirati added neuroscience, radiopharmaceuticals, and KRAS G12C oncology beyond core drugs. That broadens revenue sources and lowers reliance on a few legacy blockbusters. With Breyanzi and Abecma, Bristol Myers Squibb also runs two CAR-T assets, adding a second operating model.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 angle\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna\u003c\/td\u003e\n\u003ctd\u003eCNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayzeBio\u003c\/td\u003e\n\u003ctd\u003eRadiopharma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirati\u003c\/td\u003e\n\u003ctd\u003eKRAS G12C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53649422188886,"sku":"bms-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/bms-ansoff-analysis.webp?v=1778877800","url":"https:\/\/balancedscorecardexamples.com\/products\/bms-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}